RECRUITING

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

Conditions

End Stage Kidney Disease Renal Disease Hemodialysis Complication Kidney Diseases Dialysis Renal Dialysis Hemodialysis, Home Renal Insufficiency Kidney Failure, Chronic

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners

Official Title

Prospective, Non-Randomized, Multicenter, Open-Label Study Evaluating the Use of the Moda-flx Hemodialysis System™ Under Professional Care and At Home by Participants With End Stage Kidney Disease (ESKD) Who Are on Stable Dialysis Regimens

Quick Facts

Study Start:2025-09

Study Completion:2027-09

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06613568

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Are between 18 and 80 years of age and Care Partner is at least 18 years of age at the time of signing consent. * Have a diagnosis of end stage kidney disease (ESKD) adequately treated by maintenance dialysis (defined as achieving a spKt/V ≥ 1.2 OR stdKt/V ≥ 2.1) and be deemed stable by their treating nephrologist prior to the end of the Screening Period * Have a well-functioning and stable vascular access (tunneled central venous catheter arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min prior to the end of Screening * Can successfully complete a Skills and Comprehension Assessment with a Care Partner prior to the completion of the Training Period.	* Hgb level of \< 9 g/dL at Screening * Symptomatic intradialytic hypotension requiring medical intervention (ultrafiltration turned off, bolus of fluid) in at least two treatments during the Run-In period defined as: 1. Persistent pre-dialysis sitting SBP \< 100 mmHg despite medical therapy, 2. Nadir intradialytic Systolic Blood Pressure (SBP) \< 90 mmHg, if Subject's pre-HD SBP \< 160 mmHg 3. Nadir intradialytic SBP \< 100 mmHg if Subject's pre-HD SBP ≥ 160 mmHg * Documented history of non-adherence to dialysis therapy that would prevent successful completion of the study * Participant had an average ultrafiltration rate \> 13 mL/kg/hour during the last 2 weeks prior to Screening, per medical records. * Had a significant cardiovascular adverse event within the last 90 days prior to Screening.

Inclusion Criteria

Exclusion Criteria

* Are between 18 and 80 years of age and Care Partner is at least 18 years of age at the time of signing consent.
* Have a diagnosis of end stage kidney disease (ESKD) adequately treated by maintenance dialysis (defined as achieving a spKt/V ≥ 1.2 OR stdKt/V ≥ 2.1) and be deemed stable by their treating nephrologist prior to the end of the Screening Period
* Have a well-functioning and stable vascular access (tunneled central venous catheter arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min prior to the end of Screening
* Can successfully complete a Skills and Comprehension Assessment with a Care Partner prior to the completion of the Training Period.

* Hgb level of \< 9 g/dL at Screening
* Symptomatic intradialytic hypotension requiring medical intervention (ultrafiltration turned off, bolus of fluid) in at least two treatments during the Run-In period defined as:
1. Persistent pre-dialysis sitting SBP \< 100 mmHg despite medical therapy,
2. Nadir intradialytic Systolic Blood Pressure (SBP) \< 90 mmHg, if Subject's pre-HD SBP \< 160 mmHg
3. Nadir intradialytic SBP \< 100 mmHg if Subject's pre-HD SBP ≥ 160 mmHg
* Documented history of non-adherence to dialysis therapy that would prevent successful completion of the study
* Participant had an average ultrafiltration rate \> 13 mL/kg/hour during the last 2 weeks prior to Screening, per medical records.
* Had a significant cardiovascular adverse event within the last 90 days prior to Screening.

Contacts and Locations

Study Contact

Michael Gastauer

CONTACT

949-916-5851

HomeTrial@Diality.com

Principal Investigator

Cynthia Silva, MD

STUDY_DIRECTOR

Diality Inc.

Study Locations (Sites)

aQua Research Institute, LLC

Houston, Texas, 77058

United States

Collaborators and Investigators

Sponsor: Diality Inc.

Cynthia Silva, MD, STUDY_DIRECTOR, Diality Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09

Study Completion Date2027-09

Study Record Updates

Study Start Date2025-09

Study Completion Date2027-09

Terms related to this study

Keywords Provided by Researchers

Renal Disease
Hemodialysis Complication
Kidney Diseases
Dialysis
Renal Dialysis
Hemodialysis, Home
Renal Insufficiency
Kidney Failure, Chronic

Additional Relevant MeSH Terms

End Stage Kidney Disease